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Introduction
Voltage-gated Ca 2+ channels are highly expressed in the chromaffin cells of adrenal medulla. They trigger key Ca 2+ signalling pathways that are vital for chromaffin cells functioning and for controlling catecholamine release during body requirement (García et al., 2006; Mahapatra et al., 2012) . Among the various Ca 2+ channel isoforms expressed in chromaffin cells, the L-type (Cav1) are particularly critical since they carry the largest proportion of Ca 2+ currents in the rodents and humans (García et al., 2006) . Cav1 channels are directly involved in the control of action potential firing (Marcantoni et al., 2007; 2009; 2010) , catecholamine release (García et al., 1984; Lopez et al., 1994; Kim et al., 1995; Nagayama et al., 1999; Carabelli et al., 2003) and vesicle retrieval (Rosa et al., 2007) . In addition, L-type Ca 2+ channels (LTCCs) are effectively modulated by a variety of locally released neurotransmitters or circulating hormones, which either up-or down-regulate channel gating and significantly alter the Ca 2+ influx controlling cell functioning. These receptor-mediated modulations occur through mechanisms that are either fast and localized in membrane micro-domains (Hernández-Guijo et al., 1999; Hernández et al., 2011) or slow and remote, involving intracellular second messenger cascades, like the cGMP/PKG (Carabelli et al., 2002) and the cAMP/PKA pathway (Carabelli et al., 2001; Cesetti et al., 2003) . The former is particularly effective in down-regulating LTCCs while the latter increases the open probability of LTCCs and the associated down-stream vesicle secretion (Carabelli et al., 2003) . Thus, L-type Ca 2+ currents may undergo remarkable size changes depending on the stimulus acting on chromaffin cells that could either be the consequence of the "fight-or-flight" response, with high-frequency sympathetic discharges which elevates the level of intracellular cAMP (Anderson et al., 1992; Przywara et al., 1996) , or an opposing response which increases the levels of NO and intracellular cGMP to limit Ca 2+ flux through Cav1 channels (Schwarz et al., 1998; Carabelli et al., 2002) .
The interest on LTCCs modulation by hormones and neurotransmitters is further increased in the past few years since the observation that bovine, rat and mouse chromaffin cells express the two neuronal Cav1 channel isoforms: Cav1.2 and Cav1.3 (García-Palomero et al., 2001; Baldelli et al. 2004; Marcantoni et al., 2010; Peréz-Alvarez et al., 2011) . As for the neuronal isoforms, the Cav1.2 and Cav1.3 of mouse chromaffin cells possess strong sensitivity to DHP agonists and antagonists but exhibit rather different functional properties that derive from their distinct voltage range of activation and time course of voltage-(VDI) and Ca 2+ -dependent inactivation (CDI) (Koschak et al., 2001 , Xu & Lipscombe, 2001 ). Cav1.3 activates at 10 to 20 mV more negative voltages than Cav1.2 (Mangoni et al., 2003; Lipscombe et al., 2004; Mahapatra et al., 2011) and has faster activation but slower and less complete VDI as compared to Cav1.2 (Koschak et al., 2001 , Xu & Lipscombe, 2001 ). In addition, in MCCs Cav1.3 is more tightly coupled to fast-inactivating BK channels than Cav1.2 (Marcantoni et al., 2010; Vandael et al., 2010) and is able to drive SK channels near resting potentials (Vandael et al., 2011) . All these properties explain the unique role that Cav1.3 plays in setting the pacemaking current driving action potential (AP) firings during spontaneous cell activity or regulating burst firing during prolonged depolarization. In fact, despite Cav1.2 and Cav1.3 carry equal amounts of Ca 2+ currents, loss of Cav1.3 channels in MCCs causes: i) a reduction of the Ca 2+ currents that drive AP firings in MCCs, ii) a reduced percentage of spontaneously firing cells in physiological KCl solutions and iii) anomalous AP bursts and prolonged plateau depolarizations in response to DHP agonists (Marcantoni et al., 2010; Vandael et al., 2010; Mahapatra et al., 2011) . At variance with this, Cav1.2 contributes mostly to the Ca 2+ influx during the AP upstroke and thus appears more critical in controlling Ca 2+ signalling during fast repeated depolarization.
Given these basic functional differences and the limited information presently available on PKA-and PKG-mediated modulation of Cav1.3 channels (Marshall et al., 2011; see Catteral, 2011 for a review),
we thought of interest to assay how Cav1.2 and Cav1.3 are effectively modulated by the two opposing pathways which may drive significant changes to the size of L-type currents and Ca 2+ signalling regulating chromaffin cells activity. Here, using the Cav1.3 -/-KO mouse (Platzer et al., 2000) , we compared the potentiating effect of cAMP/PKA and the inhibitory action of cGMP/PKG on the L-type currents of WT and Cav1.3 -/-KO MCCs and show that Cav1.2 and Cav1.3 are equally sensitive to the two modulatory pathways. This occurs at basal conditions, where both kinases are already active, and during PKA-or PKG-induced stimulation. The two modulatory pathways act independently on both channel isoforms, so that extreme conditions (activation of PKA and inhibition of PKG or vice versa)
induce cumulative effects leading to Ca 2+ current amplitudes that can vary by one order of magnitude (from 18 to 180% of control size). This L-type current "plasticity" may occur under elevated sympathetic stimulation during cAMP-mediated sustained release of catecholamines in response to stressful conditions (Przywara et al., 1996; Wakade, 1998) or during activation of NO/cGMP/PKG pathway to rapidly limit catecholamine release (Oset-Gasque et al., 1994; Rodríguez-Pascual, et al., 1996) pen-stript + 15% fetal bovine serum [FBS] ) and gently triturated with a 200 μl pipette tip to dissociate the cells. 100 μl of the concentrated cell suspension was then placed on a well of four-well plastic dishes, pre-treated with poly-L-ornithine (0.5 mg/ml) and laminin (10 μg/ml in L-15 carbonate), the cells were allowed to settle before supplementing with 1.9 ml of enriched DMEM solution. The plates were incubated at 37°C with 5 % CO 2 and used after 1day of incubation. Digestion-solution: 20-25 U/ml of papain (Worthington Biochemical, Lakewood, NJ, USA) + 20 μl of 0.2 mg /ml DNase (Sigma) was solubilised in 1 ml of DMEM solution (Gibco, Invitrogen) containing (in mM): 1.5 L-Cysteine, 1 M CaCl 2 0.5 mM EDTA. Washing solution: DMEM with 1 mM CaCl 2 , and 10 mg/ml bovine serum albumin (Sigma, USA). FBS (Sigma, USA) used in enriched DMEM media was priorly heat inactivated at 56 °C for 30 mins. The procedure to achieve optimal perforated-patch recording conditions with amphotericin B dissolved in dimethyl sulfoxide (DMSO) was similar to that described previously (Cesetti et al., 2003; Marcantoni et al., 2009) . Current traces were acquired at 10 kHz and filtered using a low pass Bessel filter set at 1-2 kHz. Fast capacitative transients during step depolarization were minimized on-line by the patch-clamp analog compensation. Uncompensated capacitative currents were further reduced by subtracting the averaged currents in response to P/4 hyperpolarizing pulses (Marcantoni et al., 2010) .
Methods

Ethical approval -
Liquid junction potential was not corrected since ionic content of the pipette and the bath solutions were unchanged in most experiments. All the experiments were performed at room temperature (22-25°C).
Statistical analyses were performed using SPSS statistics 20 software (IBM, USA) and all the graphs were made using Microcal Origin Pro (version 6; MA, USA). Drug effects were calculated as [100× { (control-drug) / (control)}] and the normalized percentage of Ca 2+ current changes are given as mean ± standard error of the mean (S.E.M) for a number of cells (n). Student's t-test was used to evaluate significant differences of drug effect vs. control on the same cell or between WT and KO cells. Oneway ANOVA followed by a Bonferroni post hoc test was used to determine differences on the effects of several compounds tested separately on the same cell. Statistical significance (P) was set at P < 0.05 using 2-tailed Student's t-test and one-way ANOVA. The corresponding P values are indicated as: * 0.05 > P ≥ 0.01; ** 0.01 > P ≥ 0.001; *** P < 0.001.
Solutions -Nifedipine (3 μM), H89 (5 μM), forskolin (100 μM), 8-pCPT-cGMP (cGMP; 1 mM), KT5823 (1 μM) were purchased from Sigma, while tetrodotoxin citrate (TTX; 300nM) was purchased from Tocris Bioscience (Bristol, UK). ω-conotoxin-MVIIC (ω-Ctx-MVIIC), ω-conotoxin-GVIA (ω-Ctx-GVIA), and SNX 482 were purchased from Peptide Institute (Osaka, Japan) and used for blocking P/Q, N, and R-type calcium channels as previously described (Marcantoni et al., 2010) on the cell at a rate of ~0.15 ml/min using a multi-barrelled perfusion system with five inlets and a common outlet (Carabelli et al., 1998) .
RNA extraction, reverse transcription and PCR amplification
For RNA isolation, mouse adrenal medulla were dissected with small forceps, immediately frozen in liquid nitrogen, and stored at -80°C before use. RNA was isolated using the RNeasy mini kit (QIAGEN, Hilden, Germany) following the manufacturer's instructions. After reverse transcription using Sensiscript RT kit (QIAGEN), PCR was performed with PuReTaq Ready-To-Go PCR beads (GE Healthcare, Munich, Germany) using specific primers: PKA Iα (Prkar1a NM_021880) for: 5´- 
Results
MCCs express four PKA regulatory subunits and three PKG isoforms
To validate PKA and PKG as potential proteins responsible for LTCCs phosphorylation in MCCs, in a first series of experiments we analyzed the expression of different PKA regulatory (I-α, I-β, II-α, II-β) and catalytic subunits (C-α, C-β) and PKG isoforms (Iα, Iβ and II). Their expression was verified by RT-PCR at transcriptional level in the medulla of adrenal glands isolated from 6 (1-3 months old) mice using specific primers (see Methods). The amplification products of PKA I-α, I-β, II-α, II-β, C-α, C-β and PKG Iα, Iβ and II with the appropriate size were found in murine adrenal medulla (M) as well as in brain (B), used as positive control (Fig. 1) . Given the existence of PKA and PKG isoforms in MCCs,
we next tested the effect of the two kinases on both Cav1.2 and Cav1.3 either under basal activity or under maximal stimulation.
Cav1 are the only voltage-gated Ca 2+ channels basally potentiated by PKA in MCCs
MCCs express LTCCs (Cav1) and non-LTCCs (Cav2) and exhibit I/V characteristics which peak at about +10 mV in 2 mM external Ca 2+ (Marcantoni et al., 2009; 2010) . LTCCs contribute to nearly 50% of the total Ca 2+ current activated by brief step depolarization to +10 mV. The current is carried by an almost equal ratio of Cav1.2 and Cav1.3 channels expressed in MCCs (Marcantoni et al., 2010) .
MCCs possess also basal levels of cAMP (Marcantoni et al., 2009) Fig. 2a-c ). The mean reduction of peak currents in the presence of nifedipine alone was 36.5 ± 0.9 % and not significantly different when H89 was added (37.6 ± 1.0 %, n= 9; P = 1.0) (Fig. 2d ). In four of these cells, H89 caused an apparent slight increase of the current that was, however, not statistically significant and that could be due to the removal of a PKA-mediated basal inhibition of non-L-type Cav2 channels (see below). The block by nifedipine required few seconds to reach maximal effects while inhibition by H89 was significantly slower, mostly due to its remote action on PKA and
Cav1 channels. The onset and offset of H89 action required 90-120 s to reach steady-state conditions and had no major effects on the time constant of channel activation. The mean half-time to peak (t 1/2 ) was 1.13 ± 0.07 ms without and 1.05 ± 0.05 ms with H89. In few MCCs, we also tested the effects of 1 μ M H89 (Carabelli et al., 2001 ) and found only a significantly prolonged time to reach steady-state values with no changes in the percentage of inhibition. Thus, to shorten the duration of the experiments and to limit the Ca 2+ current run-down, we opted for using H89 at 5 μ M, being aware that several kinases (S6K1, MSK1 and ROCK-II), besides PKA, could be inhibited by these concentrations (Davies et al., 2000) . These kinases, however, are not expected to contribute significantly to basal Cav1 channels phosphorylation (see Discussion).
We also found that the H89-induced inhibition was similar at different membrane potentials, as shown by the proportional depression of the I/V characteristics induced by H89 at all potentials ( application at V h = -50 mV (Marcantoni et al., 2010) . The three toxins caused a marked reduction of I Ca (54.8 ± 1.9 %) but preserved the inhibitory effects of H89 (29.4 ± 2.8 %, ***P < 0.001; n=7) ( Fig. 3a-c). Although not statistically significant, the inhibition of I Ca was slightly larger than the 25.7 % reduction observed in the absence of Cav2 channel blockers (Fig. 2d ). This could be due to the existence of an effective basal PKA-mediated up-regulation of LTCCs (~30% of the total current) and a possibly 3-4% opposite action on Cav2 channels, not clearly resolved here but supported by the data described in the following section. show equal sensitivity to PKA under basal conditions.
PKA activation equally potentiates Cav 1.2 and Cav 1.3
The potent inhibition (≈ 65%) To our surprise, however, when tested on the total Ca 2+ currents, 1-100 μ M forskolin caused either no effects or minor inhibitions (12.8 ± 0.9 % current reduction, n= 11). We never observed significant potentiating effects (Fig. 5a,b) . On the contrary, there were always large inhibitions in the presence of nifedipine (21.8 ± 2.5 %, n= 5; * P = 0.02) (Fig. 5c-e) , that suggested an hindered potentiating effect of forskolin on LTCCs. Thus, we concluded that forskolin had opposing actions on LTCCs and nonLTCCs: an up-regulatory effect on Cav1 channels that was completely hindered by a more robustinhibition of N, P/Q and R-type channels. This latter resembled the D 1 receptor-mediated inhibition of N and P/Q-channels in neostriatal (Surmeier et al., 1995) and basal forebrain neurons (Momiyama and Fukazawa., 2007) . Thus, given the existence of these two opposing actions, we decided to test the effects of forskolin (100 μ M) on LTCCs after having blocked the non-LTCCs with the toxin mixture previously used (Fig. 3a) .
As shown in Fig. 6a and 6b, the half block of Cav2 channels by the toxins (ω-Ctx-MVIIC + ω -Ctx-GVIA + SNX 482) was fast and complete within 60 s. After Cav2 channels block, the remaining LTCC currents in WT (Cav1.2 + Cav1.3) and KO MCCs (Cav1.2), were around 50% and 25% (51.7 ± 2.6 %, n=9 and 27.3 ± 1.8 %, n=8, *** P < 0.001; Fig. 6c ), indicating equal contribution of Cav1.2 and Cav1.3 channels to the toxins-resistant current. Application of forskolin (100 μ M) together with SNX led to a net potentiation of LTCCs, which was slow at the beginning, as expected for forskolin to diffuse inside the cell and activate the adenylyl cyclase. Maximal potentiation of LTTCs was achieved within 60-90 s. In WT and in KO MCCs, the I Ca increase by forskolin was of 13.4 ± 0.9 % (n= 9) and 7.2 ± 1.1 % (** P = 0.006; n= 8), respectively (Fig. 6d) . Normalization of these values to the L-type current size shows that full phosphorylation of Cav1.2 and Cav1.3 causes a ~25 % increase of L-type currents (Fig. 6e) , with no prevalence of one isoform on the other (P = 0.92). This confirms that Cav1.2 and Cav1.3 are equally prone to PKA potentiation, irrespectively of whether the V h was maintained rather negative (-80 mV) or near the resting potential (-50 mV).
As a final control we also tested if the forskolin-induced potentiation of LTCCs was prevented by H89.
Fig. 6f,g shows that this is indeed the case. After blocking the Cav2 channels by toxin mixture mentioned before the reversible potentiation of I Ca-L by forskolin was around 25 % (24.0 ± 1.5 %).
However, in presence of L type channels' inhibition by H89 (40.8 ± 2.4 %), when forskolin (100
was applied, it did not produce any further changes (40.0 ± 2.5 %; P = 0.82). Thus, supporting the conclusion that Cav1.2 and Cav1.3 of MCCs are equally sensitive to the cAMP/PKA elevation induced by forskolin and H89 fully prevents it.
cGMP selectively inhibits LTCCs
Activation of PKG is shown to inhibit neuronal LTCCs (Sumii and Sperelakis., 1995; Carabelli et al., 2002; Yang et al., 2007) , but whether this action is specific for LTCCs or could affect Cav2 channels as well has not been proved yet. To assess this issue, we first tested the inhibitory effects of the membrane permeable cGMP analogue 8-pCPT-cGMP (0.1 to 1 mM) on total I Ca in the absence and in the presence of nifedipine. As shown in Fig. 7 , 8-pCPT-cGMP (1 mM) produced a marked inhibition of total Ca 2+ currents at + 10 mV (36.5 ± 2.2 %, n= 4, Fig. 7a ) that was independent of membrane voltage as shown by the nearly identical percentage of current block from -50 to +50 mV (Fig. 7b ).
Inhibition required nearly 80-120 s to reach maximal values, was fully reversible and rather similar if using 0.1 or 1 mM 8-pCPT-cGMP (see below). Complete washing required also around 2 min. The inhibitory action of 8-pCPT-cGMP was fully prevented when LTCCs were blocked by 3
and Ca 2+ currents were carried only by Cav2 channels (Fig. 7c ). Block by nifedipine was maximal within 60 s (35.2 ± 3.3 %) and did not further increase when 8-pCPT-cGMP was applied for 120-180 sec (36.7 ± 1.7 %, n= 4; P = 1) (Fig. 7d) . To confirm that cGMP selectively acts on LTCCs, we also tested 8-pCPT-cGMP before and after blocking Cav2 channels with toxin mixture (ω-Ctx-MVIIC + ω -Ctx-GVIA + SNX 482) (Fig. 8) . Except the 1 st part of cGMP effect alone and the last part of the wash, SNX was present in all solutions, including 1 st wash. Mean percentage of inhibition was very similar:
29.5 ± 3.1 % before and 25.8 ± 3.8 % after toxins application (n= 5; P = 0.17, not significantly different), proving that cGMP acts specifically on LTCCs in MCCs.
Cav1.2 and Cav1.3 channel currents are equally sensitive to cGMP
Given that LTCCs are selectively inhibited by cGMP, we next assessed how cGMP specifically affects Cav1.2 and Ca1.3 channel currents by comparing its action on the total I Ca current in both WT and cGMP-mediated inhibition of LTCCs were slow and gradual and maximum inhibitory effect were attained within 2-3 min. Similarly, the washing followed a gradual recovery and was complete within the same amount of time. Quantitative inhibitions of I Ca in WT and KO-MCCs were 36.5 ± 2.2 % (n= 4) and 19.2 ± 0.9 %, ((** P = 0.008; n= 6) ( Fig. 9c) contribute equally to the total L-type Ca 2+ current in MCCs (Fig. 4c) , the 36% and 19% inhibition of I Ca in WT and KO MCCs indicates that both Cav1.2 and Cav1.3 are equally sensitive to the cGMPmediated inhibition.
Cav1.2 and Cav1.3 are equally down-regulated by basal PKG activation
Similarly to PKA, which shows a prominent basal activity, we tested if also PKG is active under basal conditions by using 1 μ M KT5823, which is widely recognized to be a selective PKG blocker (Wahler and Dollinger, 1995; Murthy and Makhlouf. 1995; Abi-Gerges et al., 2001; Carabelli et al., 2002; Almanza et al., 2007) , although some discrepancy exist (Burkhardt et al. 2000; Bain et al. 2003 ).
Since Cav1.2 and Cav1.3 channels are equally sensitive to cGMP-mediated inhibition, we assessed how both Cav1 isoforms are sensitive to PKG under basal conditions. We blocked PKG by using Quantitative potentiation by KT5823 in WT and KO MCCs was 20.9 ± 1.2 % (n= 11) and 9.7 ± 1.0 % (n= 7; *** P < 0.001) in WT and KO MCCs, respectively (Fig. 10c) . Thus, as for PKA, basal PKG inhibition in WT MCCs was twice as large as in KO MCCs and thus equally distributed on Cav1.2 and Cav1.3 channels.
To confirm that PKG inhibition by KT5823 selectively potentiates LTCCs, we tested the effect of the PKG blocker on cells pre-treated with 3 μ M nifedipine. The DHP completely prevented the potentiating effect of KT5823 in WT MCCs (Fig. 10d) , thus confirming that PKG-mediated phosphorylation selectively inhibits LTCCs at basal levels. Mean block by nifedipine was 47.6 ± 1.6 % (V h = -50 mV) and was nearly unaffected (48.2 ± 1.9 %, n = 6; P = 0.63) by KT 5823 (Fig. 10e ). In conclusion, in MCCs exists a selective and prominent PKG-mediated basal inhibition of LTCCs which equally affects Cav1.2 and Cav1.3 channels. As a final control we tested whether KT5823 was able to prevent the inhibitory effects of PKG in MCCs. Fig. 10f ,g shows the response of a representative cell, where exposure of 1 μ M KT5823 potentiates the I Ca (21.4 ± 1.5 %) and fully prevents the inhibitory action of PKG (20.8 ± 1.7 %; P = 0.78) when elevated by 8-pCPT-cGMP (0.1 mM). Subsequent exposure to 8-pCPT-cGMP alone caused an average inhibition of 26.5 ± 2.2 %, (n = 4) that is not significantly different from that observed with 1 mM cGMP (29.5 ± 3.1 %, P = 0.78; Fig. 8c ).
PKA and PKG act synergistically and can induce extreme up and down-modulation of Cav1 currents
The coexistence of opposing actions of PKG and PKA on Cav1.2 and Cav1.3 channels suggests that L-type currents can potentially undergo extreme variations if the two pathways act independently on LTCCs and are opposingly activated, i.e., if one pathway is activated and the other is inhibited at the same time. We tested this possibility by first activating PKA using forskolin and subsequently inhibiting PKG by applying KT 5823 to attain maximal up-regulation of L-type currents. Fig. 11a shows that after blocking non-L-type currents with a toxin mixture containing MVIIC (10
and SNX (400 nM) (trace b), exposure to forskolin alone caused a 32.4 ± 0.7 % potentiation, while addition of KT 5823 increased the current by 45.3 ± 0.9 % to give an overall synergistic potentiation of 77.7 ± 0.5 % (n=4; *** P < 0.001). The opposite was obtained when PKA inhibition by H89 was followed by PKG activation with 8-pCPT-cGMP (Fig.11b) . L-type currents persisting after blocking the non-LTCCs (trace b1) were down regulated by 42.3 ± 1.9 % with H89 and a further 44.1 ± 4.5 % after addition of 8-pCPT-cGMP, to give an overall inhibition of 86.3 ± 5.8 % in n = 4 MCCs (*** P < 0.001).
We also found that by inverting the order of PKA and PKG modulators the results remained unchanged (data not shown), proving that both isoforms have distinct phosphorylation sites and that each phosphorylation pathway acts independently on Cav1.2 and Cav1.3 channels. In conclusion, the two opposing synergistic modulations of LTCCs are capable of generating L-type currents of one order of magnitude different amplitude: varying from a minimum of ~18 % (PKG-up, PKA-down) to a maximum of ~180 % (PKA-up, PKG-down) of control currents. This issue highlight the important role that PKA and PKG play in the modulation of LTCCs in MCCs.
Discussion
We provided evidence that the two LTCC isoforms expressed in MCCs, Cav1 Of relevance is the observation that Cav1.3 is equally modulated as Cav1.2, whose gating modifications by PKA and PKG have been extensively studied at the whole-cell and single channel level in cardiac cells (Bean et al., 1984; Hartzell & Fischmeister, 1986; Méry et al., 1993; Jiang et al., 2000) . Little is known about the modulatory properties of native Cav1.3 channels (Catterall, 2011 ) and the present findings should partially overcome this missing information. Bock et al., 2011) .
We have also shown that cAMP/PKA and cGMP/PKG modulations act independently on Cav1 channels and their effects are cumulative. This is most evident when one pathway is activated and the other is inhibited. The two actions sum-up markedly, regardless of the sequential order in which activation and inhibition occur (Mahapatra, Carabelli, Carbone, unpublished observations) and lead to extreme L-type current variations which can differ by one order of magnitude (from 18 to 180 % of the control current) under extreme stimulation of one pathway and inhibition of the other. Comparable extreme effects are reported also for cardiac Ca 2+ currents when separately enhanced by cAMP/PKA or down-regulated by cGMP/PKG (Hartzell & Fischmeister, 1986; Méry et al., 1993; Catterall, 2011) .
To our knowledge, the combined PKA-and PKG-mediated cumulative modulation of I Ca-L reported here represents one of the most impressive change of L-type current amplitude driven by intracellular modulatory pathways, which is analogous to a ten-fold increase of Ca 2+ channel density and represents a quick "cell plasticity" change in a tissue where LTCCs regulate key cellular functions.
The cAMP/PKA-mediated up-regulation of Cav1.2 and Cav1.3 in MCCs
We have shown that like Cav1.2, also Cav1. A cAMP/PKA-mediated up-regulation of Cav1.2 and Cav1.3 is expected to exhibit also a potentiating effect on the Ca 2+ -dependent catecholamine secretion which increases proportionally to the Ca 2+ influx and the cAMP-mediated downstream processes controlling secretion (Carabelli et al., 2003) .
Since, most of the secretion in chromaffin cells is uniformly controlled by all the Ca 2+ channel types expressed in these cells (N, P/Q, R, L) (Engisch & Nowycky, 1996; Klinghauf & Neher, 1997; Carabelli et al., 2003; Marcantoni et al., 2007), Cav1.2 and Cav1. 3 are expected to contribute to vesicle fusion and catecholamine release proportionally to their increased current, without any specific preference for either one isoform. Obviously, since the two channels possess distinct voltagedependent activation and inactivation kinetics (Koschak et al., 2001 , Xu & Lipscombe, 2001 Concerning the modulatory effects of cAMP/PKA on Ca 2+ currents, it is important to recall that, in contrast to LTCCs, the Cav2 channels (N, P/Q, R) are partially inhibited by forskolin and this action masks LTCCs potentiation induced by the adenylate cyclase (AC) activator ( Fig. 5 and 6 ). This occurs also in neostriatal dopaminergic neurones (Surmeier et al., 1995) and basal forebrain neurones (Momiyama & Fukazawa, 2007) , where activation of dopamine D 1 -receptors causes a PKA-mediated down-regulation of N-and P/Q-type channels which is prevented by PKA inhibitors. Similar to chromaffin cells, the up-regulation of LTCCs could be observed in a subset of neostriatal neurones only after blocking N-and P/Q-type channels (Surmeier et al., 1995) . Regarding the possibilities that other protein kinases, besides PKA, could be involved in the up-regulation of Cav1 channels we should recall that the potentiating action of forskolin is fully prevented by H89 in MCCs (Fig. 6f) and that at the doses tested (1-5 μ M) only few kinases (S6K1, MSK1, ROCK-II) could be inhibited by H89 (Davies et al., 2000) . These kinases, however, are mainly involved in nuclear signalling pathways leading to cell growth and metabolism, inflammation and oxidative stress and other functions. Their modulatory effects develop slowly with time and there is no evidence supporting any specific action on Cav1 channels (Fenton and Gout., 2011; Mifsud et al., 2011; de-Godoy and Rattan, 2011) .
The cGMP/PKG-mediated down-regulation of Cav1.2 and Cav1.3
We have clearly shown that L-type currents are effectively down-regulated by the cGMP/PKG signalling pathway, in good agreement with a number of reports on cardiac (Tohse & Sperelakis, 1991; Jiang et al., 2000; Yang et al., 2007) , smooth muscles (Tewari & Simard, 1997; Ruiz-Velasco et al., 1998) , neuronal (Kim et al., 2000; Nishiyama et al., 2003; Almanza et al., 2007; Lv et al., 2010) and chromaffin cells (Carabelli et al., 2002) . Most of the studies report specific down-regulations of Cav1.2 that are likely mediated by two serine sites located on the α1 subunit (Ser-1928 and Ser-533) (De Jongh et al., 1996; Jiang et al., 2000; Yang et al., 2007) while nothing is known about the downregulation of recombinant Cav1.3 α1 isoform and the location of serine phosphorylation sites for PKG.
The only available data on Cav1.3 modulation by cGMP/PKG comes from a study on the NOmediated down-regulation of L-type currents in rat vestibular hair cells, which are mainly carried by Cav1.3 channels (Almanza et al., 2007) . This work shows that part of the NO-induced inhibition of Cav1.3 is mediated by the cGMP/PKG pathway, thus proving an effective down-regulation of Cav1.3 channels by PKG (see also Lv et al., 2010) . Our data are in very good agreement with these findings and show that the down-regulation of Cav1.3 is comparable with that of Cav1.2. The two isoforms are equally modulated at basal conditions and during stimulation with 8-pCPT-cGMP (Fig. 9, 10 ).
As previously noticed (Carabelli et al., 2002) our findings exclude also the possibility that the inhibitory effects of PKG on Cav1.2 and Cav1.3 channels derives from the activation of a cGMP-dependent cAMP-phosphodiesterase (PDE) which lowers the level of cAMP and reverses the cAMP-mediated up regulation of LTCCs activity. This action is typical of cardiac Cav1.2 channels (Méry et al., 1993; Wahler & Dollinger, 1995) and differs markedly from the one mediated by PKG described here.
Indeed, we clearly showed that the inhibitory action of cGMP proceeds regardless of whether the cAMP/PKA pathway is fully blocked by H89 (Fig. 11b) or is maintained at sufficiently high levels under basal conditions in WT and Cav1.3 -/-KO MCCs (Fig. 9 ). This occurs also during single channel recordings in bovine (Carabelli et al., 2002) and mouse chromaffin cells (Mahapatra, Carabelli & Carbone, unpublished observations) and proves that the two signalling pathways (cAMP/PKA and cGMP/PKG) affect mainly Cav1 channel gating without interfering with each other, most likely by phosphorylating distinct sites. In bovine chromaffin cells, PKG activation has identical inhibitory effects on L-type channel gating regardless of whether PKA is blocked by H89 or fully activated by 8-CPT-cAMP (Carabelli et al., 2002) .
The synergistic effects of PKA and PKG on Cav1.2 and Ca1.3
An important issue of our work is that among the Ca 2+ channel types expressed in MCCs, PKA and PKG mostly affect the LTCCs. PKG has no action on Cav2 channels (Fig. 7) while PKA has a partial inhibitory effect only during forskolin stimulation (Fig. 5) . The two kinases, however, act independently on both Cav1.2 and Cav1.3 isoforms and under extreme conditions of full up-regulation of one enzyme and down-regulation of the other, the effects become cumulative to give L-type Ca 2+ currents 20 of ten-fold different size. This is of great interest since these conditions may occur during chromaffin cell functioning and can be extrapolated to other cell tissues possessing the same signalling pathways (Ruiz-Velasco et al. 1998; Almanza et al., 2007) . 
Functional implications of PKA and PKG modulation on Cav1 channels
As shown here and in previous works (Carabelli et al., 2001; Cesetti et al., 2003 ) the cAMP/PKA and cGMP/PKG pathways are already active at rest due to the basal activity of the two cyclases (AC and GC). AC is mainly activated by PACAP (Przywara et al., 1996) , Ca 2+ entry and αGs subunits that are activated by the basal activity of hormones and neurotransmitters released by sympathetic neurons (Anderson et al., 1992) , surrounding capillaries (Marley, 2003; Wilson, 1988) and by the autocrine activity of chromaffin cells (Currie & Fox, 1996; Carabelli et al., 1998; Cesetti et al., 2003) . This latter, is most likely the cause of the high basal level of cAMP in culture conditions (2.2 mM) that raises 2 to 3-fold following β 1 -adrenoreceptors (β 1 -AR) stimulation and/or PDEs selective inhibition (Marcantoni et al., 2009) . The soluble GC is activated by the resting NO levels generated by the Ca 2+ /calmodulinmediated activation of NO-synthase (NOS) expressed in most chromaffin cells (Oset-Gasque et al., 1994; Schwarz et al., 1998) . Under these conditions, cGMP/PKG appears to work as a "break" to limit the potentiating effects of cAMP/PKA and helps setting the resting levels of Cav1.2 and Cav1.3 currents.
A potentiating synergistic effect of PKA and PKG could occur during sustained sympathetic The-cGMP analogue in the presence of nife produced no significant difference to the current block from nifedipine alone (P = 1). vs. cGMP block alone and in the presence of toxin-block is statistically different (*** P < 0.001, using one-way ANOVA followed by Bonferroni post hoc test). The cGMP effects before and after toxin treatment are not statistically different (P = 0.17, using Student's t-test). C, Mean basal I Ca potentiation by KT 5823 in WT (n= 11) and in KO MCCs (n= 7), indicating significant differences (*** P < 0.001, using unpaired Student's t-test).
D, The selective PKG inhibitor KT5823 doesn't produce any I Ca potentiation in the presence of nifedipine. The inset shows the current traces recorded at the time indicated by the letters.
E, The mean I Ca inhibitions with nifedipine alone and in presence of KT5823 (1 μM) are nearly identical (P = 0.63, using Student's t-test), indicating that the potentiating effect of KT5823 is prevented when LTCCs are blocked by nife. 
